Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...

Pfizer's vaccine for Clostridium difficile (C. US biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. diff.) infection by ...

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in ...

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff.

Symptoms range from mild to severe and can lead to complications such as dehydration, bloody stool, low blood pressure, rapid heart rate and infection in the tissues of the colon. C. diff infection is ...

Opinion: The FDA must act so patients with refractory C. difficile infection can access lifesaving fecal transplants.

Also known as fecal microbiota transplant, or FMT, the treatment involves inoculating the colon with healthy donor stool.

C. diff spreads via the spores it produces. They are very hard to eradicate completely, which is why this infection is often seen in hospitals and long-term care settings. Treatment depends on the ...

Ferring Pharmaceuticals today announced three poster presentations at the American College of Gastroenterology’s annual ...

Every year, the medical community recognizes the month of November as Clostridioides difficile (C. diff) Awareness month. C.

Fecal microbiota transplants, or FMTs, are a magic bullet for patients with recurring infections from Clostridioides difficile (C. diff), but researchers are only beginning to understand why.